99tcm-mibi scintimammography for the detection of breast malignancies the contribution of the count ratio to specificity

Nuclear Medicine Communications

Volumn 20, Issue 6, 1999, Pages 511-516

  Horne, T ^a   Pappo, I ^a   Cohenpour, M ^a   Mindlin, L ^a   Orda, R ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

DIAGNOSTIC AGENT; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; RADIOPHARMACEUTICAL AGENT; PERTECHNETIC ACID TC 99M;

ADOLESCENT; ADULT; AGED; ARTICLE; BREAST TUMOR; FEMALE; HUMAN; LABORATORY DIAGNOSIS; MIDDLE AGED; PATHOLOGY; PREDICTION AND FORECASTING; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; BREAST CANCER; DIAGNOSTIC ACCURACY; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; SCINTIMAMMOGRAPHY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; FALSE NEGATIVE REACTIONS; FALSE POSITIVE REACTIONS; FEMALE; HUMANS; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY; TECHNETIUM TC 99M SESTAMIBI;

EID: 0033144157     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1080/00006231-199906000-00004     Document Type: Article

References (26)

1. Kelsey JI, Gammon MD. The epidemiology of breast cancer. Cancer 1991; 41: 146-165.
2. Barchana M, Andreev H, Alon R. Cancer in Israel. Israel Cancer Registry 1994: 10-12.
3. Shapiro S, Venet W, Strax R Ten to fourteen year effect of screening on breast cancer mortality. J Natl Cancer Inst 1982; 69: 349-355.
4. Lopez MJ, Blackwell CW. Breast cancer detected by screening: The importance of long-term follow-up. Surgery 1989; 106: 5590-5595.
5. Tabar L, Fagerberg GJG, Gad A et al. Reduction in mortality from breast cancer after mass screening with mammography: Rantrial from the Breast Screening Working Group of the Swedish National Board of Health and Welfare. Lancet 1985; 1: 829-832.
6. Bjurstam N, Bjorneld L, Duffy SW et al. The Gothenburg breast screening trial: First results on mortality, incidence, and mode of detection for women aged 39^49 years at randomization. Cancer 1997; 80: 2091-2099.
7. Kopans DB. Imaging analysis of breast lesions. In: Harris JR, Lippmann ME, Morrow M, Heilman S, eds. Diseases of the breast. Philadelphia, PA: Lippincott-Raven, 1996: 71-84.
8. Caner B, Kitapcl M, Unlu M et al. Technetium-99m-MIBI uptake in benign and malignant bone lesions: A comparative study with technetium-99m-MDP. J Nucl Med 1992; 33: 319-324.
9. O'Tuama LA, Packard AB, Treves SD. SPECT imaging of pediatric brain tumors with hexakis (methoxyisobutyliso-nitrile) technetium I. J Nucl Med 1990; 31: 2040-2041.
10. Balon HR, Fink-Bennet DM, Stoffer SS. Technetium-99m uptake by recurrent Hurtle cell carcinoma of the thyroid. J Nucl Med 1992; 33: 1393-1395.
11. Taillefer R, Boucher Y, Potvin C, Lambert R. Detection and localization of parathyroid adenomas in patients with hyperparathyroidism using a single radionuclide imaging procedure with technetium-99m-sestamibi (double-phase study). J Nucl Med 1992; 33: 1801-1807.
12. Khalkhali I, Cutrone J, Mena I et al. Technetium-99m-sestamibi scintimammography of breast lesions: Clinical and pathological follow-up. J Nucl Med 1995; 36: 1784-1789.
13. Khalkhali I, Mena I, Jouanne E et al. Prone scintimammography in patients with suspicion of carcinoma of the breast. J Am Coll Surg 1994; 178: 491-497.
14. Maublant J, Delatur M, Mestas D et al. Technetium-99m-sestamibi uptake in breast tumour and associated lymph nodes. J Nucl Med 1996; 37: 922-925.
15. Villanueva-Meyer J, Leonard MH Jr, Briscoe E et al. Mam-moscintigraphy with technetium-99m-sestamibi in suspected breast cancer. J Nucl Med 1996; 37: 926-930.
16. Palmedo H, Schomburg A, Grunwald F et al. Technetium-99m-MIBI scintimammography for suspicious breast lesions. J Nucl Med 1996; 37: 626-630.
17. Pappo I, Horne T, Reif R et al. The use of technetium-99m-sestamibi (MIBI) for the detection of breast malignancies. Society of Surgical Oncology, 50th Annual Symposium, Chicago, 1997 (abstract).
18. 99m-MIBI) breast scintigraphy for early detection of breast cancer. In: Bergmann D, Kroiss A, Sinzinger H, eds. Radioactive isotopes in clinical medicine and research XXII. Basel: Birkhauser Verlag, 1997: 43-49.
19. Stowasser G, Pernegger C, Brinninger G et al. Evaluation of Tc-99m sestamibi (MIBI) in patients with suspected breast cancer in comparison with Tl-201 (abstract). J Nucl Med 1994; 35: 231P.
20. 99mTc sestamibi in tumor imaging. In: Freeman LM, ed. Nuclear medicine annual. New York: Raven Press, 1994: 181-234.
21. Maublant JC, Zheng Z, Rapp M et al. In vitro uptake of technetium-99m-teboroxime in carcinoma cell lines and normal cells: Comparison with technetium-99m-sestamibi and thallium-201. J Nucl Med 1993; 34: 1949-1952.
22. Rao VV, Chiu ML, Kronauge JF et al. Expression of recombinant human multi-drug resistance P-glycoprotein in insect cells confers decreased accumulation of technetium-99m-sestamibi. J Nucl Med 1994; 35: 510-515.
23. Moretti JL, Azaloux H, Boisseron D et al. Primary breast cancer imaging with technetium-99m sestamibi and its relation with P-glycoprotein over-expression. Eur J Nucl Med 1996; 23: 980-986.
24. m-MIBI mammoscintigraphy of breast masses: Early and delayed imaging. Nucl Med Commun 1995; 16: 150-156.
25. Maurer AH, Caroline DF, Jadali FJ et al. Limitations of craniocaudal thallium-201 and technetium-99m-sestamibi mammoscintigraphy. J Nucl Med 1995; 36: 1696-1700.
26. Mansi L, Rambaldi PF, Procaccini E et al. Scintimammography with technetium-99m tetrofosmin in the diagnosis of breast cancer and lymph node métastasés. Eur J Nucl Med 1996; 23: 932-939.